FDA is aware that some patients and health care professionals may look to unapproved versions of GLP-1 – glucagon-like peptide-1 receptor agonists – drugs, including semaglutide and tirzepatide, as an ...

GLP-1s can deliver value to patients. But the fact that GLP-1s aren't cost-effective at their current net prices can limit ...

Medications like Ozempic and Mounjaro work by mimicking naturally occurring hormones in the body, such as glucagon-like ...

Two new class action complaints, both captioned Robins v. Lemme Inc., were filed in in California Superior Court and the Southern District of New ...

Even a little weight loss can work wonders for your health. A study found that people at high risk for developing type 2 diabetes who lost 5-7% of their weight had a 58% lower risk of developing it.

Hims & Hers Health ( HIMS 3.08%) stock jumped 2.2% through 10:45 a.m. ET Monday after Morgan Stanley analyst Craig Hettenbach ...

“Whether consumers are using GLP-1 medications for weight management or are reducing sugar intake as part of their overall ...

There’s no question that the wildly popular injectable weight-loss drugs help people drop pounds, lower heart-disease risk, ...

Amid the soaring use of glucagon-like peptide-1 (GLP-1) drugs for intentional weight loss, a vastly different movement appears to be gaining traction in health care: Many clinicians are pushing for a ...

Chilean AI-led food tech startup NotCo has unveiled a botanical GLP Booster powder that uses food as a natural Ozempic ...

Weight loss from glucagon-like peptide 1 agonists clearly alleviates knee osteoarthritis pain, but other recently published data give pause regarding possible long-term adverse effects.

People without diabetes can lose up to 13% of their starting weight in 6 months using tirzepatide (Mounjaro) as an off-label ...